F. Giles
About
F. Giles is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, F. Giles has authored 18 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 14 papers in Genetics and 6 papers in Rheumatology. Recurrent topics in F. Giles's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Lymphoblastic Leukemia research (6 papers). F. Giles is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Lymphoblastic Leukemia research (6 papers). F. Giles collaborates with scholars based in United States, Germany and Italy. F. Giles's co-authors include Hagop M. Kantarjian, Michele Baccarani, J M Goldman, Philippe Martiat, Kapil N. Bhalla, Jörge E. Cortes, John Gow, Norbert Ifrah, Feyruz V. Rassool and Gareth J. Morgan and has published in prestigious journals such as Journal of Clinical Oncology, Blood Cancer Journal and HemaSphere.
In The Last Decade
F. Giles
18 papers receiving 228 citations
Peers
F. Giles
Sven Schwemmers Germany
Kathleen C. Rayeroux Australia
Lucy C. Crossman United States
Pamela Acha Spain
Tina L. Hamilton United Kingdom
Peter A. te Boekhorst Netherlands
Hajime Akada United States
Wanke Zhao United States
B. Hilda Ye United States
Sivahari Prasad Gorantla Germany
Citations per year, relative to F. Giles F. Giles (= 1×)
peers
Sven Schwemmers
Countries citing papers authored by F. Giles
Since
Specialization
Citations
This map shows the geographic impact of F. Giles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Giles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Giles more than expected).
Fields of papers citing papers by F. Giles
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by F. Giles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Giles. The network helps show where F. Giles may publish in the future.
Co-authorship network of co-authors of F. Giles
This figure shows the co-authorship network connecting the top 25 collaborators of F. Giles. A scholar is included among the top collaborators of F. Giles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Giles. F. Giles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ross, David M., Tamás Masszi, Andrzej Hellmann, et al.. (2019). PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192‐WK RESULTS. HemaSphere. 3(S1). 157–157.
2.
Hochhaus, Andreas, Carlo Gambacorti‐Passerini, Camille N. Abboud, et al.. (2019). PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. HemaSphere. 3(S1). 535–535.
3.
Wolf, Dominik, Satu Mustjoki, Bjørn Tore Gjertsen, et al.. (2016). Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP). Pure Amsterdam UMC. 39. 39–39.
4.
Seymour, John F., D. W. Kim, Abebe Haregewoin, et al.. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4(8). e238–e238.
5.
Coutre, Philipp D. le, F. Giles, Andreas Hochhaus, et al.. (2009). Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. Journal of Clinical Oncology. 27(15_suppl). 7057–7057.
6.
Kantarjian, Hagop M., F. Giles, Kapil N. Bhalla, et al.. (2009). Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. Journal of Clinical Oncology. 27(15_suppl). 7029–7029.
7.
Rosti, G., Philipp le Coutre, Kapil N. Bhalla, et al.. (2007). A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Journal of Clinical Oncology. 25(18_suppl). 7007–7007.
8.
Larson, Richard A., Hagop M. Kantarjian, Philipp le Coutre, et al.. (2007). A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 25(18_suppl). 7040–7040.
9.
Coutre, Philipp le, Norbert Gattermann, Andreas Hochhaus, et al.. (2007). A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Journal of Clinical Oncology. 25(18_suppl). 7026–7026.
10.
Tanaka, Chiaki, Theodore A Smith, Hagop M. Kantarjian, et al.. (2006). Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL). Journal of Clinical Oncology. 24(18_suppl). 3095–3095.
11.
Coutre, Philipp D. le, Oliver G. Ottmann, Richard A. Larson, et al.. (2006). A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). Journal of Clinical Oncology. 24(18_suppl). 6531–6531.
12.
Jabbour, Elias, F. Giles, Jörge E. Cortes, et al.. (2006). Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Journal of Clinical Oncology. 24(18_suppl). 6591–6591.
13.
Estrov, Zeev, F. Giles, G. Borthakur, et al.. (2006). Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) following treatment failure with imatinib mesylate and AMN107. Journal of Clinical Oncology. 24(18_suppl). 6530–6530.
14.
Kantarjian, Hagop M., Norbert Gattermann, S G O'Brien, et al.. (2006). A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). Journal of Clinical Oncology. 24(18_suppl). 6534–6534.
15.
Karp, Judith E., David A. Rizzieri, Norbert Vey, et al.. (2006). Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML. Journal of Clinical Oncology. 24(18_suppl). 6512–6512.
16.
Gerson, S L, S. O’Brien, Verena Karsten, et al.. (2005). Analysis of pre-treatment O6-alkylguanine transferase (AGT) levels in patients (pts) with hematologic malignancies receiving VNP40101M (101M). Journal of Clinical Oncology. 23(16_suppl). 6542–6542.
17.
Fischer, Thomas, Akash Patnaik, Kapil N. Bhalla, et al.. (2005). Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. Journal of Clinical Oncology. 23(16_suppl). 3106–3106.
18.
Martiat, Philippe, Norbert Ifrah, Feyruz V. Rassool, et al.. (1989). Molecular analysis of Philadelphia positive essential thrombocythemia.. PubMed. 3(8). 563–5.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sven Schwemmers Breakdown of academic impact, for papers by Kathleen C. Rayeroux Breakdown of academic impact, for papers by Lucy C. Crossman Breakdown of academic impact, for papers by Pamela Acha Breakdown of academic impact, for papers by Tina L. Hamilton Breakdown of academic impact, for papers by Peter A. te Boekhorst Breakdown of academic impact, for papers by Hajime Akada Breakdown of academic impact, for papers by Wanke Zhao Breakdown of academic impact, for papers by B. Hilda Ye Breakdown of academic impact, for papers by Sivahari Prasad Gorantla